本文選題：髓勞病　切入點(diǎn)：貧血　出處：《黑龍江中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:采用補(bǔ)腎生血法對(duì)30例慢性髓勞病患者治療6個(gè)月,通過外周血象、中醫(yī)證候積分等數(shù)據(jù)的療前、療后對(duì)比,觀察補(bǔ)腎生血法治療慢性髓勞病的臨床療效及療前療后骨髓中Kv1.3mRNA表達(dá)水平的差異性變化,并與10位志愿者組成的健康對(duì)照組進(jìn)行對(duì)比,以了解慢性髓勞病患者Kv1.3mRNA表達(dá)水平與正常人之間的差異性。探討Kv1.3mRNA表達(dá)水平變化與慢性髓勞病發(fā)病機(jī)制之間可能存在的關(guān)系,從而推測(cè)補(bǔ)腎生血法治療慢性髓勞病可能存在的的療效機(jī)理。方法:①選擇30位已確診的慢性髓勞病患者為治療組,采用補(bǔ)腎生血法對(duì)這些患者進(jìn)行為期6個(gè)月的治療,觀察并記錄這些患者的臨床療效、中醫(yī)證候積分及外周血象等在治療前后的變化;②采集這些患者用補(bǔ)腎生血法治療前后的骨髓,采用RT-PCR法檢測(cè)骨髓液中Kv1.3mRNA表達(dá)水平治療前后的變化。結(jié)果:①患者經(jīng)補(bǔ)腎生血法治療的臨床有效率為80.0%,患者經(jīng)補(bǔ)腎生血法治療六個(gè)月后癥狀均有明顯好轉(zhuǎn),中醫(yī)證候積分較療前也顯著降低,差異有統(tǒng)計(jì)學(xué)意義(P0.05);②治療后患者外周血血象各項(xiàng)指標(biāo)明顯升高,差異有統(tǒng)計(jì)學(xué)意義(P0.05);③患者骨髓中Kv1.3mRNA表達(dá)水平在經(jīng)過補(bǔ)腎生血法治療六個(gè)月后,表達(dá)水平明顯上升,但仍低于健康對(duì)照組骨髓中Kv1.3mRNA的表達(dá)水平,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:①補(bǔ)腎生血法對(duì)于慢性髓勞病的臨床治療具有肯定意義,無論在降低中醫(yī)證候積分、改善中醫(yī)證候、還是提高外周血象等方面都取得了顯著的療效。②慢性髓勞患者Kv1.3mRNA表達(dá)水平的低表達(dá)狀態(tài)可能與慢性髓勞的病機(jī)存在某種關(guān)系。③補(bǔ)腎生血法可能通過調(diào)節(jié)Kv1.3mRNA表達(dá)水平而調(diào)節(jié)整合素介導(dǎo)的造血微環(huán)境損傷,從而提高骨髓造血能力,促進(jìn)造血干/祖細(xì)胞的增殖分化,最終達(dá)到治療慢性髓勞病的目的。
[Abstract]:Objective: to treat 30 patients with chronic pulpitis for 6 months by tonifying the kidney and generating blood, and to compare the data before and after treatment with the data of peripheral blood picture and TCM syndromes integral, etc. To observe the clinical effect of tonifying kidney and blood generating method in treating chronic myellabour disease and the difference of Kv1.3mRNA expression in bone marrow after treatment, and to compare it with the healthy control group composed of 10 volunteers. In order to understand the difference between the expression of Kv1.3mRNA in patients with chronic myellabour disease and normal subjects, and to explore the possible relationship between the changes of Kv1.3mRNA expression and the pathogenesis of chronic myellabour disease. Thus, the possible therapeutic mechanism of tonifying the kidney and generating blood was speculated. Methods 30 patients with chronic myellabour disease were selected as the treatment group and treated for 6 months with the method of tonifying kidney and generating blood. Observe and record the clinical curative effect of these patients, TCM syndromes integral and peripheral blood image changes before and after treatment to collect the bone marrow of these patients before and after treatment with the method of tonifying kidney and generating blood. RT-PCR method was used to detect the changes of Kv1.3mRNA expression in bone marrow fluid before and after treatment. Results the clinical effective rate of Bushen Shengxue therapy was 80.00.The symptoms of the patients treated with Bushen Shengxue method for six months were obviously improved. The score of TCM syndromes was also significantly lower than that before treatment. The difference was statistically significant (P 0.05). After treatment, the indexes of peripheral blood were significantly increased, and the level of Kv1.3mRNA expression in bone marrow of patients with P0.05 + 3 was significantly increased after six months of treatment with Bushen and Xue. The expression level of Kv1.3mRNA in bone marrow of healthy control group was significantly higher than that of healthy control group (P 0.05). Conclusion the method of tonifying kidney and generating blood by 1% 1 has positive significance for the clinical treatment of chronic Myelopathy, regardless of decreasing the integral of TCM syndromes. Improve TCM syndromes, The low expression level of Kv1.3mRNA in patients with chronic myelosis may have some relationship with the pathogenesis of chronic myelosis. 3 the method of tonifying kidney and generating blood may regulate the water expression of Kv1.3mRNA. Mediating integrin mediated hematopoietic microenvironment injury, Thus, the hematopoiesis ability of bone marrow was improved, and the proliferation and differentiation of hematopoietic stem / progenitor cells were promoted.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李靜;賈國榮;劉學(xué)文;;再生障礙性貧血的發(fā)病機(jī)制的研究進(jìn)展[J];中國實(shí)驗(yàn)診斷學(xué);2017年01期

2 李乃謙;;熟地黃活性成分藥理作用的研究進(jìn)展[J];中國處方藥;2017年01期

3 劉佳;趙海平;李春義;;鹿茸成分研究進(jìn)展[J];特產(chǎn)研究;2016年04期

4 王亞非;李運(yùn)海;邢姝琴;李彥;伊力扎提;商曉迪;趙東方;柏立群;;巴戟天有效成分及其治療腎陽虛證的研究進(jìn)展[J];中華中醫(yī)藥雜志;2016年12期

5 李欽;胡繼宏;高博;李海東;宋爽;楊麗霞;;黃芪多糖在免疫調(diào)節(jié)方面的最新研究進(jìn)展[J];中國實(shí)驗(yàn)方劑學(xué)雜志;2017年02期

6 徐亞文;滕瑛鈺;劉奇峰;劉大同;;劉大同教授從毒論治再生障礙性貧血[J];長春中醫(yī)藥大學(xué)學(xué)報(bào);2016年03期

7 鄧婷;婁世鋒;;免疫抑制劑治療再生障礙性貧血的研究進(jìn)展[J];現(xiàn)代醫(yī)藥衛(wèi)生;2016年11期

8 申攀;李剛;;王祥麒教授治療再生障礙性貧血經(jīng)驗(yàn)[J];中醫(yī)研究;2016年05期

9 趙文靜;王歷;王芝蘭;旺建偉;常惟智;孫敏;柴劍波;曲苗;曹靜;;淫羊藿的藥理作用及臨床應(yīng)用研究進(jìn)展[J];中醫(yī)藥信息;2016年02期

10 劉威;;雄激素與環(huán)孢素A治療再生障礙性貧血的對(duì)比分析[J];中國醫(yī)藥指南;2016年02期

，

本文編號(hào)：1626725